Results 21 to 30 of about 170,256 (261)

Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome

OncoImmunology, 2022
The PD-1 inhibitor pembrolizumab is effective in treating Sézary syndrome, a leukemic variant of cutaneous T-cell lymphoma. Our purpose was to investigate the effects of pembrolizumab on healthy and malignant T cells in Sézary syndrome and to discover ...
Tianying Su, George E. Duran, Alexa C. Kwang, Nirasha Ramchurren, Steven P. Fling, Youn H. Kim, Michael S. Khodadoust   +6 more
doaj   +1 more source

Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature

Thoracic Cancer, 2020
Several studies have demonstrated increased pericardial effusion during anti‐PD‐1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial.
Kazuaki Harada, Makoto Ogasawara, Akane Shido, Akimitsu Meno, Soichiro Oda, Shota Yoshida, Sonoe Yoshida, Ayumu Yoshikawa, Ko Ebata, Satoshi Abiko, Naoki Kawagishi, Itsuki Sano, Hisashi Oda, Takuto Miyagishima   +13 more
doaj   +1 more source

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

, 2020
BACKGROUND Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy.
García Carbonero, Rocío, André, Thierry, Díaz, Luis A.   +2 more
core   +1 more source

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis

Thoracic Cancer, 2019
Recent clinical trials have demonstrated that anti‐PD‐1 blocking antibodies showed remarkable clinical efficacy in a subset of non‐small cell lung cancer (NSCLC) patients.
Akio Osa, Takeshi Uenami, Yujiro Naito, Haruhiko Hirata, Shohei Koyama, Takayuki Takimoto, Takayuki Shiroyama, Shinji Futami, Saeko Nakatsubo, Nobuhiko Sawa, Yukihiro Yano, Izumi Nagatomo, Yoshito Takeda, Masahide Mori, Hiroshi Kida, Atsushi Kumanogoh   +15 more
doaj   +1 more source

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study

Cancer Medicine, 2023
Background The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untreated advanced ...
Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita   +15 more
doaj   +1 more source

Pembrolizumab: An Immunotherapeutic Agent Causing Endocrinopathies. [PDF]

, 2020
Pembrolizumab is an immune checkpoint inhibitor (programmed cell death 1) approved for use in non-small cell lung carcinoma (NSCLC). Pembrolizumab has shown remarkable results in regression of the size of tumors in NSCLC and has shown survival advantage.
Chaudry, Abdul, Chaudry, Misbat, MD, Aslam, Jonaid, MD   +2 more
core   +1 more source

A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency

Case Reports in Oncology, 2021
Pembrolizumab is an anti-programmed cell death protein-1 antibody that is mainly used for the treatment of non-small cell lung cancer (NSCLC). Immune-related adverse events can be caused by immune checkpoint inhibitors; however, few case reports evaluate
Kei Sonehara, Kazunari Tateishi, Taro Hirabayashi, Taisuke Araki, Yuichi Ikuyama, Ryosuke Machida, Masayuki Hanaoka   +6 more
doaj   +1 more source

Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series [PDF]

The use of immune checkpoint inhibitors is increasing every day. With such frequent use, the side effects and management associated with these treatments are becoming difficult. One of rare side effects is autoimmune diabetes mellitus. In this review, we
Aslı GEÇGEL, Erhan GÖKMEN, Oğuzcan ÖZKAN   +2 more
core   +1 more source

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact

Therapeutic Advances in Medical Oncology
Background: Pembrolizumab plus chemotherapy (Pembrolizumab-CT) has been suggested as first-line treatment over pembrolizumab alone in aggressive non-small-cell lung cancer (NSCLC) with ⩾50% PDL1, but studies comparing these two strategies are lacking ...
Marine Lejeune, Eric Wasielewski, Vincent Leroy, Soraya Bordier, Arnaud Scherpereel, Alexis Cortot, Clément Gauvain   +6 more
doaj   +1 more source

Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer

Acta Oncologica
Background and purpose: Neoadjuvant therapy (NAT) has become standard therapy for early triple-negative breast cancer (TNBC). The aim of this study was to report real-world outcome of TNBC treated with NAT with or without pembrolizumab and to identify ...
Johanna Mattson, Meeri Maunu, Juho Lähteenmaa, Peeter Karihtala, Suvi Tuohinen, Joonas Laaksolilja, Anders Ståhls, Tuomo Meretoja   +7 more
doaj   +1 more source